Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 83,256 | 89,841 | 41,312 | 55,176 | 67,465 |
| Receivables | 2,328 | 2,622 | 2,254 | 2,021 | 4,244 |
| Inventories | 193 | 1,077 | 1,082 | 1,160 | 1,160 |
| TOTAL | $89,498 | $98,431 | $49,324 | $62,677 | $74,442 |
| Non-Current Assets | |||||
| PPE Net | 1,847 | 1,961 | 2,162 | 2,486 | 2,708 |
| TOTAL | $1,847 | $1,961 | $2,162 | $2,486 | $2,708 |
| Total Assets | $91,345 | $100,392 | $51,486 | $65,163 | $77,150 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,820 | 1,828 | 2,101 | 4,250 | 2,821 |
| Accrued Expenses | 8,606 | 5,053 | 4,135 | 4,084 | 6,084 |
| TOTAL | $15,343 | $11,781 | $11,062 | $13,761 | $14,397 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 2,917 | 4,901 | 4,826 | 5,427 | 5,493 |
| TOTAL | $55,651 | $53,607 | $54,541 | $54,595 | $55,849 |
| Total Liabilities | $70,994 | $65,388 | $65,603 | $68,355 | $70,246 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 101,390 | 100,435 | 92,025 | 91,890 | 91,712 |
| Common Shares | 101 | 100 | 92 | 92 | 92 |
| Retained earnings | -225,252 | -208,358 | -195,949 | -183,798 | -172,010 |
| TOTAL | $20,352 | $35,004 | $-14,117 | $-3,192 | $6,903 |
| Total Liabilities And Equity | $91,345 | $100,392 | $51,486 | $65,164 | $77,149 |